Article thumbnail

Re-evaluating early breast neoplasia

By Sharon Moulis and Dennis C Sgroi

Abstract

Historically, histomorphological and epidemiological data suggested that atypical ductal hyperplasia and ductal carcinoma in situ are the earliest recognizable neoplastic stages of breast cancer progression. Over the past several years, detailed high-throughput molecular genetic, gene expression and epigenetic analyses have enhanced our understanding of these early neoplastic lesions and have re-shaped our view of human breast cancer progression to include multiple distinct pathways of evolution

Topics: Viewpoint
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2374963
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1998). Allred DC: Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci.
  2. (2006). CL: Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors.
  3. (2006). Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res
  4. (2004). DC: A twogene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell
  5. (2003). DC: Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA
  6. (1985). DL: Risk factors for breast cancer in women with proliferative breast disease.
  7. (2007). EM: HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
  8. (2003). ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA
  9. (2006). EV: Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression. Cancer Res
  10. (2006). FJ: A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res
  11. (2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
  12. (1990). HJ: A comparison of the results of longterm follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer
  13. (2003). IO: The diagnosis and management of preinvasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) - current definitions and classification. Breast Cancer Res
  14. (2003). K: Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res
  15. (2006). LD: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer.
  16. (2001). Lønning PE, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA
  17. (1997). Merino MJ: Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast.
  18. (2006). Proliferation: the most prominent predictor of clinical outcome in breast cancer. Cell Cycle
  19. (1999). The transition from hyperplasia to invasive carcinoma of the breast.
  20. (1999). W: Comparative genomic hybridization of ductal carcinoma in situ of the breast - evidence of multiple genetic pathways.